Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
GlucoTrack Inc (GCTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: GCTK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -31.28% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.72M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.19 | 52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 |
52 Weeks Range 5.16 - 3756.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3442.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -161.01% | Return on Equity (TTM) -694.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5064418 | Price to Sales(TTM) - |
Enterprise Value -5064418 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.01 | Shares Outstanding 567456 | Shares Floating 428235 |
Shares Outstanding 567456 | Shares Floating 428235 | ||
Percent Insiders 8.84 | Percent Institutions 1.27 |
Upturn AI SWOT
GlucoTrack Inc
Company Overview
History and Background
GlucoTrack Inc. (GTKI) was founded in 2011 with the goal of developing and commercializing non-invasive glucose monitoring technologies. The company has faced several developmental and regulatory hurdles since its inception, focusing on bringing innovative solutions to the diabetes management market. Its evolution has been marked by shifts in product focus and strategic partnerships as it navigated the complex medical device landscape.
Core Business Areas
- Diabetes Monitoring Technology: Development and commercialization of non-invasive glucose monitoring devices. This includes research and development into wearable sensors and advanced algorithms for continuous glucose tracking.
Leadership and Structure
GlucoTrack Inc.'s leadership team typically comprises individuals with expertise in medical devices, engineering, and business management. The organizational structure is generally focused on R&D, regulatory affairs, manufacturing, and sales.
Top Products and Market Share
Key Offerings
- Product Name 1: The company's primary focus has been on its non-invasive glucose monitoring technology. While specific market share data is not readily available due to the product's developmental stage and potential market entry, its primary competitors in the broader glucose monitoring market include Dexcom (DXCM) with its G6/G7 Continuous Glucose Monitoring (CGM) system and Abbott Laboratories (ABT) with its FreeStyle Libre system.
Market Dynamics
Industry Overview
The diabetes management industry, particularly glucose monitoring, is a rapidly growing and highly competitive market driven by the increasing global prevalence of diabetes. Key trends include the shift towards continuous glucose monitoring (CGM) and the integration of data into comprehensive diabetes management platforms. Technological advancements are crucial for market players.
Positioning
GlucoTrack Inc. aims to position itself as a disruptor in the glucose monitoring market by offering a non-invasive alternative to existing invasive or minimally invasive technologies. Its competitive advantage would lie in the ability to provide a comfortable, pain-free, and continuous monitoring solution.
Total Addressable Market (TAM)
The global diabetes care market is valued in the hundreds of billions of dollars and is projected to grow significantly. The specific TAM for glucose monitoring devices is a substantial portion of this, estimated to be tens of billions of dollars. GlucoTrack Inc. is positioned to capture a segment of this market if it can successfully bring its non-invasive technology to commercial viability and widespread adoption, competing with established players who hold significant market share.
Upturn SWOT Analysis
Strengths
- Innovative non-invasive technology
- Potential for pain-free glucose monitoring
- Focus on a large and growing market
Weaknesses
- Limited historical financial performance and profitability
- Unproven commercial viability and regulatory approvals
- Dependence on significant R&D investment
- Lack of established market presence compared to competitors
Opportunities
- Increasing global prevalence of diabetes
- Growing demand for convenient and less invasive health monitoring
- Potential for strategic partnerships with larger healthcare companies
- Technological advancements in sensor technology and AI
Threats
- Intense competition from established players with existing market share
- Regulatory hurdles and lengthy approval processes
- Rapid technological advancements by competitors
- Challenges in manufacturing scalability and cost-effectiveness
- Potential for disruptive technologies from other innovators
Competitors and Market Share
Key Competitors
- Dexcom, Inc. (DXCM)
- Abbott Laboratories (ABT)
- Medtronic plc (MDT)
Competitive Landscape
GlucoTrack Inc.'s main disadvantage is its lack of commercialized products and established market presence, while its advantage lies in its novel non-invasive approach. Competitors have a significant lead in terms of market share, customer base, and revenue, but GlucoTrack Inc.'s technology could offer a differentiated value proposition if successful.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for GlucoTrack Inc. has been primarily in its technological development and intellectual property portfolio, rather than revenue or user growth.
Future Projections: Future growth projections are highly speculative and contingent on successful clinical trials, regulatory approvals, and market adoption of its non-invasive glucose monitoring technology. Analyst estimates, if available, would be based on these critical milestones.
Recent Initiatives: Recent initiatives would likely involve ongoing R&D, seeking strategic partnerships, engaging with regulatory bodies, and securing further funding to advance product development.
Summary
GlucoTrack Inc. is an early-stage company with innovative potential in the non-invasive glucose monitoring space. Its core strength lies in its technology, but it faces significant challenges related to commercialization, regulatory hurdles, and intense competition from established players. Successful future growth is contingent on overcoming these obstacles and securing market acceptance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GlucoTrack Inc
Exchange NASDAQ | Headquaters Rutherford, NJ, United States | ||
IPO Launch date 2013-04-25 | CEO, President & Director Mr. Paul V. Goode Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 11 | Website https://glucotrack.com |
Full time employees 11 | Website https://glucotrack.com | ||
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack, a non-invasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain through a small sensor clipped onto the earlobe. It is also developing the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.